UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 32

Sortiert nach

1246 Immune related adverse events to checkpoint inhibitors are associated with altered regulatory T cell phenotypes and resemble CTLA4-deficient patients

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1378-A1378

2023

Link zum Volltext

Verfügbarkeit prüfen

906 Immunogenomic evaluation of clear cell renal carcinoma uncovers HK3 as a myeloid specific metabolic enzyme

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A951-A951

2021

Link zum Volltext

Verfügbarkeit prüfen

Endogenous retrovirus expression and its impact on tumor-infiltrating immune cells in papillary renal cell carcinoma

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.453-453

2024

Link zum Volltext

Verfügbarkeit prüfen

Biomarker-driven prospective clinical trial in renal cell carcinoma: Developing machine learning models to allocate patients to treatment arms using RNA sequencing

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4525-4525

2023

Link zum Volltext

Verfügbarkeit prüfen

The effect of loss of SETD2 on mitochondrial dysfunction in clear cell renal cell carcinoma

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.567-567

2019

Link zum Volltext

Verfügbarkeit prüfen

Effect of erythropoietin-stimulating agent use on belzutifan antitumor activity in patients with VHL disease–associated renal cell carcinoma: Post hoc analysis of the LITESPARK-004 study

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.3-3

2024

Link zum Volltext

Verfügbarkeit prüfen

Initial screening efforts for the OPTIC RCC trial

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.478-478

2024

Link zum Volltext

Verfügbarkeit prüfen

A multi-center retrospective cohort study of patients with mCRPC who received lutetium Lu177 vipivotide tetraxetan

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.89-89

2024

Link zum Volltext

Verfügbarkeit prüfen

TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4605-TPS4605

2022

Link zum Volltext

Verfügbarkeit prüfen

Association between tumor burden and response to immunotherapy in patients with metastatic renal cell carcinoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4541-4541

2022

Link zum Volltext

Verfügbarkeit prüfen

TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.TPS405-TPS405

2022

Link zum Volltext

Verfügbarkeit prüfen

Initial results from the phase 1 study of ARO-HIF2 to silence HIF2-alpha in patients with advanced ccRCC (AROHIF21001)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.339-339

2022

Link zum Volltext

Verfügbarkeit prüfen

Belzutifan treatment for von Hippel-Lindau (VHL) disease–associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2008-2008

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.666-666

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of intermittent therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with front-line ipilimumab and nivolumab (Ipi/Nivo)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.672-672

2023

Link zum Volltext

Verfügbarkeit prüfen

Optimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS742-TPS742

2023

Link zum Volltext

Verfügbarkeit prüfen

Association of the neutrophil to eosinophil ratio with response to immunotherapy-based combinations in metastatic renal cell carcinoma

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.341-341

2021

Link zum Volltext

Verfügbarkeit prüfen

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carcinoma who have received front-line treatment (NCT04300140)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4511-4511

2022

Link zum Volltext

Verfügbarkeit prüfen

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib, cabozantinib and nivolumab, and as monotherapy in patients with advanced or metastatic clear cell renal cell carcinoma (NCT04300140)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4599-TPS4599

2022

Link zum Volltext

Verfügbarkeit prüfen

Association between on-treatment eosinophil dynamics and outcomes in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.364-364

2022

Link zum Volltext

Verfügbarkeit prüfen

Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4553-4553

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II study of vorolanib plus nivolumab in patients with thoracic malignancies: immunotherapy (IO) correlatives to differentiate responders from nonresponders

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e21019-e21019

2020

Link zum Volltext

Verfügbarkeit prüfen

Metabolic barriers to immunotherapy in renal cell carcinoma

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.11560-11560

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Thema

Kidney Cancer
(2)
Regular And Young Investigator Award Abstracts
(2)
Best Practice
(1)
Biomarkers
(1)
Bone Marrow
(1)
Breast Cancer
(1)
Cancer
(1)
Carcinoma, Renal Cell - Diagnosis
(1)
Carcinoma, Renal Cell - Genetics
(1)
Carcinoma, Renal Cell - Therapy
(1)
Clinical Trials
(1)
Consent
(1)
Digital Health
(1)
Enzymes
(1)
Genetic Testing
(1)
Genomes
(1)
Glucose
(1)
Health Education
(1)
Health Websites
(1)
Hematology
(1)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

1246 Immune related adverse events to checkpoint inhibitors are associated with altered regulatory T cell phenotypes and resemble CTLA4-deficient patients

906 Immunogenomic evaluation of clear cell renal carcinoma uncovers HK3 as a myeloid specific metabolic enzyme

Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study

Endogenous retrovirus expression and its impact on tumor-infiltrating immune cells in papillary renal cell carcinoma

Biomarker-driven prospective clinical trial in renal cell carcinoma: Developing machine learning models to allocate patients to treatment arms using RNA sequencing

The effect of loss of SETD2 on mitochondrial dysfunction in clear cell renal cell carcinoma

Effect of erythropoietin-stimulating agent use on belzutifan antitumor activity in patients with VHL disease–associated renal cell carcinoma: Post hoc analysis of the LITESPARK-004 study

Initial screening efforts for the OPTIC RCC trial

A multi-center retrospective cohort study of patients with mCRPC who received lutetium Lu177 vipivotide tetraxetan

TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor

Association between tumor burden and response to immunotherapy in patients with metastatic renal cell carcinoma

TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor

Initial results from the phase 1 study of ARO-HIF2 to silence HIF2-alpha in patients with advanced ccRCC (AROHIF21001)

Belzutifan treatment for von Hippel-Lindau (VHL) disease–associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC)

Phase II trial of intermittent therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with front-line ipilimumab and nivolumab (Ipi/Nivo)

Optimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC)

Association of the neutrophil to eosinophil ratio with response to immunotherapy-based combinations in metastatic renal cell carcinoma

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carcinoma who have received front-line treatment (NCT04300140)

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib, cabozantinib and nivolumab, and as monotherapy in patients with advanced or metastatic clear cell renal cell carcinoma (NCT04300140)

Association between on-treatment eosinophil dynamics and outcomes in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab

Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study

Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC)

Phase I/II study of vorolanib plus nivolumab in patients with thoracic malignancies: immunotherapy (IO) correlatives to differentiate responders from nonresponders

Metabolic barriers to immunotherapy in renal cell carcinoma

Suchergebnisse filtern